Results 191 to 200 of about 2,408,520 (295)

Sonogenetics Nanomedicine Activates the cGAS‐STING Pathway for Immunotherapy of Triple‐Negative Breast Cancer

open access: yesAdvanced Science, EarlyView.
A HER3‐targeted sonogenetic lipid nanoparticle platform is developed for triple‐negative breast cancer therapy. An AI‐designed miniprotein inhibits HER3 signaling, while TRPV4 and NFAT‐responsive IL‐15 plasmids enable ultrasound‐controlled calcium signaling and cytokine expression. The system induces Ca2+ overload, ROS generation, mitochondrial damage,
Junya Song   +6 more
wiley   +1 more source

Temporal Trajectories of the Tau Aggregate Interactome Reveal Stage‐Specific Vulnerabilities in Alzheimer's Disease

open access: yesAdvanced Science, EarlyView.
Tau populations with different aggregation states associate with distinct sets of proteins in the Alzheimer's disease brain. Proteomic discovery combined with single‐molecule analysis in neurons reveals dynamic associations involving proteostasis, metabolism and RNA biology.
Dorothea Böken   +8 more
wiley   +1 more source

CHD8‐Dependent Chromatin Licensing Sustains Trophoblast Stem Cell Transcriptional Programs

open access: yesAdvanced Science, EarlyView.
In this study, Huang et al., identify chromatin remodeler CHD8 as an essential factor in TSC maintenance and placental development. CHD8‐dependent chromatin accessibility supports the occupancy of key trophoblast TFs and is coupled to KMT2A‐associated H3K4me3 deposition at TSC stem and cell cycle genes, providing a permissive chromatin environment for ...
Yuanyuan Huang   +16 more
wiley   +1 more source

FBP1‐Mediated Compartmentalization of Glycolytic Enzyme Complexes Suppresses PKM2 Function to Ameliorate MASLD Progression

open access: yesAdvanced Science, EarlyView.
In normal hepatocytes, FBP1 forms compartmentalized complexes with PKM2, ENO1, and LDHA independent of its catalytic activity, inhibiting PKM2 activity and restricting excessive glycolysis. During MASLD progression, FBP1 downregulation markedly reduces the abundance of these complexes and releases the “hijacked” glycolytic enzymes, leading to PKM2 ...
Busong Wang   +10 more
wiley   +1 more source

TROP2‐Targeting Chimeras (TRTACs) for Tumor Cell‐Selective Membrane Protein Degradation and Enhanced Drug Delivery

open access: yesAdvanced Science, EarlyView.
TROP2 is identified as a novel tumor‐selective lysosomal‐targeting receptor with established clinical relevance. TROP2‐targeting chimeras (TRTACs) are developed by genetically fusing a TROP2‐binding nanobody to nanobodies against specific target proteins.
Luping Chen   +10 more
wiley   +1 more source

Psychometric Properties of the 7-Item Sense of Competence Questionnaire: Assessing Informal Caregivers' Self-Perceived Competence in Mild Cognitive Impairment. [PDF]

open access: yesNeurol Ther
Manzano S   +13 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy